ESR Group Shares Rise After Starwood Capital's Plans to Acquire Stake
By Sherry Qin
Shares of real-estate manager ESR Group rose sharply after an affiliate of private investment firm Starwood Capital Group agreed to acquire a stake in the Hong Kong-listed company.
ESR Group's shares surged 11% on Wednesday morning to 8.62 Hong Kong dollars (US$1.10) after rising by as much as 14% earlier.
Sequoia Investco, a company controlled by Starwood Capital, agreed to acquire a 10.657% stake in ESR from Redwood Investment and repay all outstanding sums under an existing margin loan facility of Redwood, ESR said in an exchange filing Wednesday. Redwood Investment is controlled by two ESR directors, including Co-Chief Executive Stuart Gibson.
Earlier this month, ESR divested its ARA Private Funds business in Australia, Singapore, South Korea and the U.S. for an enterprise value of US$270.0 million to pare down debt.
ESR primarily engages in building and managing logistics properties, such as warehouses and distribution centers. It manages around US$150 billion in total assets across Asia-Pacific, Europe and North America.
Write to Sherry Qin at sherry.qin@wsj.com
(END) Dow Jones Newswires
March 19, 2024 23:07 ET (03:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks